Patients with early-stage triple-negative breast cancer, if diagnosed in time and selected for surgical treatment in time, the survival rate after surgery can reach about 30%, and the five-year survival rate is no more than 30%. Because triple-negative breast cancer is prone to local recurrence or distant metastasis within 1-3 years after surgery. Triple-negative breast cancer is not sensitive to endocrine therapy, so after the return of pathology results after surgery, intravenous chemotherapy should be chosen in a timely manner, with the aim of controlling tumor development. Commonly used drug choice, docetaxel combined with injectable cisplatin can be applied. During the treatment period, attention should be paid to hydration, diuresis, monitoring changes in blood routine and liver and kidney function indicators. After surgery, patients with triple-negative breast cancer should also undergo regular ultrasound examinations, as well as tumor marker tests and other reviews.